HIPAA-Compliant Marketing Infrastructure Is Turning Into a Growth Category in Healthcare
As OCR keeps tracking technologies under a tighter HIPAA lens, healthcare marketers still need attribution, audience building and measurement. That gap is creating room for vendors like Ours Privacy to position compliance not as a brake on growth, but as the infrastructure that makes growth possible.
Key takeaway
The real story is not the funding round. It is that HIPAA-compliant analytics, attribution and customer data infrastructure are becoming a growth category in healthcare, because marketers still need performance measurement even as tracking rules make older tooling riskier.
When tracking becomes a compliance problem, marketing becomes an infrastructure problem
For healthcare marketers, the uncomfortable reality is that the tools long treated as normal digital plumbing can become legal and procurement headaches under HIPAA. HHS OCR says regulated entities are not permitted to use tracking technologies in a way that results in impermissible disclosures of PHI to tracking technology vendors. It also says disclosures of PHI to tracking technology vendors for marketing purposes, without HIPAA-compliant authorization, are impermissible disclosures.
That matters because OCR’s guidance explicitly identifies common tools and scripts used across modern marketing stacks, including cookies, web beacons or tracking pixels, session replay scripts and fingerprinting scripts. In other words, the issue is not abstract. It reaches into the mechanics of campaign measurement, retargeting, conversion tracking and web analytics.
For commercial teams in healthcare, this is why the debate is no longer just “Are we compliant?” It is also “How do we keep acquiring patients, measuring demand and proving ROI without creating PHI exposure?”
The business problem behind the privacy rule
The tension is straightforward: healthcare marketers still need to know which campaigns drive traffic, which channels create demand and which audiences convert. But if the infrastructure used to do that exposes PHI, the marketing function can quickly become a compliance risk.
OCR’s baseline also clarifies the vendor side of the equation. If a vendor creates, receives, maintains or transmits PHI on behalf of a regulated entity for a covered function, the vendor is a business associate and a BAA is required. That means the marketing stack is not just a software decision; it is a governance decision, a procurement decision and often a legal one too.
For healthcare organizations, that changes the buying criteria. The value proposition is no longer only campaign performance. It also includes risk reduction, vendor consolidation and a cleaner path through security review.
Ours Privacy is pitching compliance as a growth stack
Ours Privacy publicly describes itself as a HIPAA-compliant CDP and privacy platform for healthcare marketing. The company says it enables HIPAA-safe performance marketing and analytics, and its homepage frames the product as a way to combine privacy and growth in one stack.
That framing is commercially important. The strongest positioning shift here is from “privacy tool” to “growth stack.” Instead of presenting compliance as a defensive layer added to marketing, Ours Privacy is trying to make compliance the foundation for acquisition and attribution.
The company says it has signed BAAs, SOC 2 Type II, USA-hosted infrastructure and no AI data training. It also says it serves over 200 healthcare organizations and processes billions of data points monthly. Those are company claims, but they are clearly being used as trust signals for buyers who worry about data exposure, procurement friction and security review.
Its pricing tells you how the company wants to sell
The pricing structure is as revealing as the product description. Ours Privacy says pricing is based on monthly tracked users, integrations needed and customer support. That is not the language of self-serve software for a low-stakes buyer. It suggests a sales-led, consultative motion that scales with customer complexity.
The company lists four tiers: Essential, Core, Enterprise and Enterprise+. Essential is positioned for pre-launch start-ups, single-location hospitals and small medical practices. Core is for most healthcare organizations running digital marketing. Enterprise is for large health systems, MSOs, DSOs and national digital health companies operating at scale. Enterprise+ is for industry-leading healthcare brands with complex operations and unique requirements.
That segmentation is a deliberate vertical packaging strategy. It maps the same core promise onto buyers that have very different governance needs, traffic volumes and integration requirements. It also shows that the vendor is not trying to win only one buyer type. It is trying to become the default privacy and measurement layer across a wide span of healthcare commercial organizations.
Each plan includes a HIPAA-compliant customer data platform and a 99.95% SLA for data collection, according to the pricing page. The company also says custom plans tailored to customer needs are available. Taken together, the public packaging points toward enterprise-style buying: scoped implementation, solution design and likely salesperson-led qualification rather than a simple checkout flow.
The stack is broader than compliance alone
Ours Privacy says the platform includes customer data platform, consent management, analytics and attribution, server-side tag manager, A/B testing and personalization, session replay, audience builder, embedded maps and videos, translations and an agentic web scanner. The homepage and pricing page also list integrations with Google Tag Manager, GA4, Google Ads, Meta, EHRs such as Epic/MyChart and Athena Health, CRM tools, warehouse destinations, call tracking and consent management.
That breadth matters because it suggests the company is trying to replace multiple point solutions with one platform. In healthcare, that can be appealing for at least three reasons: fewer vendors to govern, fewer tools to reconcile across legal and security reviews, and a more unified path from traffic to attribution to segmentation.
The commercial logic is clear. If you can preserve measurement while reducing privacy risk, you are not selling a compliance checkbox. You are selling operational continuity.
What is verified, and what is still just a claim
The independent evidence here is strong on the regulatory baseline and on market direction, but weaker on performance claims. HHS OCR independently establishes that tracking technologies can create HIPAA risk when they result in impermissible PHI disclosures, and that a BAA is required when a tracking technology vendor handles PHI on behalf of a covered entity for a covered function.
A trade publication reported that Ours Privacy raised $15 million in an oversubscribed Series A round led by Lightbank and Health Velocity Capital. That same coverage described the company as a HIPAA-compliant marketing and data infrastructure platform and a full-stack marketing solution designed with healthcare privacy in mind. It also said the company works with over 200 providers, payers, digital health companies and more, including multi-billion-dollar healthcare organizations.
But some of the sharper commercial claims remain self-reported. Ours Privacy says clients often see approximately 2x reduction in CAC compared with flying blind. There is no independently verified case study or benchmark in the supplied material to confirm that. For buyers, that means the claim is directional, not proven evidence.
Why the Tealium case study matters
A separate vendor case study gives useful context for how healthcare organizations are actually responding to OCR guidance. It describes a major US health system that moved toward HIPAA-compliant analytics after OCR’s 2022 online tracking guidance. According to the case study, the organization selected a vendor in part because it offered a Business Associate Agreement and implemented a compliant analytics framework that restored visitor traffic, referrer and UTM-based campaign reporting.
That is the practical pattern worth watching. Healthcare teams often do not start by rebuilding the entire marketing stack. They start by restoring compliant analytics. Then they expand into the next layer: customer data platform capabilities, segmentation and more sophisticated measurement.
That phased approach is commercially important for vendors because it suggests the initial purchase may be about recovering visibility, while the longer-term expansion opportunity is about deepening into identity, audience and lifecycle measurement.
What healthcare marketers should take from this
The market signal is bigger than one funding round. Ours Privacy’s packaging reflects a broader shift in healthcare marketing: privacy infrastructure is becoming part of growth infrastructure.
That shift changes how teams should think about the stack. First-party data is no longer just a nice-to-have for future-proofing. In healthcare, it is increasingly the practical answer to a regulatory environment that makes easy third-party tracking risky.
It also changes vendor selection. BAAs, SOC 2 Type II and U.S.-hosted infrastructure are not just security badges. They are part of the commercial pitch to procurement, compliance and legal stakeholders who can delay or derail a marketing purchase.
Finally, it changes the role of attribution. The goal is not to maximize measurement at any cost. It is to preserve enough measurement to run a modern growth engine while staying inside HIPAA boundaries.
That is why the category matters. If healthcare marketers cannot use the tools they used before, the winners will be the vendors that make compliant measurement feel operationally simple, not just legally safe.